Heart Health Depends on Sticking With GLP‑1 Drugs

A new study shows that the heart protection you get from GLP‑1 medicines fades quickly once you stop taking them. Researchers examined records of more than 333, 000 people with type‑2 diabetes who were treated through the Veterans Health Administration. Those on GLP‑1 drugs, such as semaglutide (Ozempic) or tirzepatide (Mounjaro), had an 18 % lower risk of heart attacks, strokes or death compared with people on sulfonylureas. The study split the GLP‑1 group into those who kept taking the medication for about three years and those who stopped. After just six months off the drug, heart‑related risk rose by 4 %. One year after stopping, it increased by 14 %, and by the second year it was up 22 %. In other words, the benefit that took three years to build disappeared in only a year and a half. The authors describe this rapid loss as “metabolic whiplash. ” They argue that while it takes years to accumulate the heart protection, only a few months are needed for the body to lose that advantage.Other research, such as the SELECT trial, found a similar 20 % reduction in major heart events with semaglutide for obesity. Those benefits appeared even when weight loss was not achieved, hinting that GLP‑1 drugs may act directly on heart tissue. Despite these findings, many patients discontinue the medication within a year, mainly because of side effects or cost. Around half give up due to nausea, fatigue or lack of insurance coverage after reaching a weight goal. The new study leaves unanswered whether maintaining a lower dose or keeping the same weight loss can preserve heart benefits once the drug is stopped. What matters most is that continuous use of GLP‑1 medicines appears essential for people who want to keep their heart health on track. Insurers and patients should recognize that stopping the drug can expose people to unnecessary risk.